Key clinical point: The presence of complex karyotype does not affect overall survival in patients with relapsed/refractory chronic lymphocytic leukemia who are treated with idelalisib.

Major finding: Among patients who received idelalisib plus rituximab, the median overall survival was 28.3 months in the complex karyotype–positive group and 49.7 months in the complex karyotype–negative group (P = .2099).

Study details: An analysis of data from 120 patients enrolled in a phase 3 trial and an extension study.

Disclosures: Both trials were sponsored by Gilead. The researchers reported relationships, including employment, with Gilead and other companies. They also disclosed funding from the German government and from nonprofit organizations in Germany.